Benchmark Initiates Coverage On Augmedix with Buy Rating, Announces Price Target of $6
Benchmark analyst Bill Sutherland initiates coverage on Augmedix (NASDAQ:AUGX) with a Buy rating and announces Price Target of $6.
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
All news is property of their respective owners.
